Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is a global leader in the healthcare industry, with a diverse portfolio of products focused on cardiovascular and diabetes devices, nutritional products, and diagnostic equipment. The company's recent FDA approval for its TactiFlex Duo product, along with its strong pipeline and market-leading position in high-growth areas, position it well for continued success in the future. While there are risks associated with the competitive landscape and potential delays in product launches, Abbott's strong financials and focus on high-growth areas make it a positive investment opportunity.

Bears say

Abbott Laboratories is facing several challenges in its different business segments including pricing pressure in its global nutrition business, pricing and procedure volume pressure in its medical devices unit, and regulatory timing for product approvals. The company also faces risks associated with predicting demand for product launches in emerging markets. Despite positive data from its FlexPulse IDE study, the outlook for its Medical Devices and Diagnostics segment remains uncertain. While the company has demonstrated strong performance in its U.S. cardiology business and expects a recovery in its nutrition business, there are still risks involved in achieving its projected acceleration in the second half of the year. Additionally, potential risks such as healthcare policy changes, competition, and government regulations could impact the company's financials and future growth.

Abbott Labs (ABT) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 20 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $124.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $124.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.